Top Markets
#1 Nesa Nesa +337.53%
#2 EXOD EXOD +22.78%
#3 MetaDAO MetaDAO +17.01%
#4 Status Status +12.64%
#5 Wrapped NXM Wrapped NXM +7.23%
#6 Kinesis Silver Kinesis Silver +6.60%
#7 Venom Venom +5.81%
#8 Tornado Cash Tornado Cash +4.89%
#9 HOME HOME +4.80%
#10 Ontology Gas Ontology Gas +3.99%
Coin of the day
Nesa Nesa
설정
언어
한국어
통화
USD
테마
Adagene Inc. Adagene Inc.

Adagene Inc.

ADAG
주식 순위 #19939
Adagene Inc. functions as a clinical-stage biopharmaceutical organization,... Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
주가
$3.88
마지막 동기화: 2026-08-25
시가총액
$146.08M
변동 (1일)
-0.51%
변동 (1년)
63.71%
국가
CN
거래 Adagene Inc. (ADAG)

카테고리

Healthcare
Adagene Inc. (ADAG)의 배당 수익률 기록
Adagene Inc. (주식 심볼: ADAG)의 배당 수익률 (TTM)은 2026 기준으로 0입니다.
지난 5년 평균 배당 수익률: 0.00%
Adagene Inc. (ADAG)의 배당 수익률 기록: 2026 ~ 2026
연도별 말 기준 배당 수익률 (TTM)
연도 배당 수익률 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 배당 수익률 (TTM)
회사 배당 수익률 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.12%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH